HMGB1 and breast carcinoma: As shown in Figure 9A, the higher risk score was significantly associated with higher expression of some negative immune checkpoint molecules in breast cancer patients, including CTLA4, CD276, TIGIT, PVR, HMGB1, TDO2, IDO1, CXCL9, and CXCL10.